-IndiaToday.in A study published in the prestigious medical journal Lancet has found that some antiviral medications might have the potential to shorten symptoms of monkeypox and reduce the amount of time a patient is contagious. Nearly 20 countries where monkeypox is not endemic have reported outbreaks of the viral disease, with more than 100 confirmed or suspected infections mostly in Europe. The outbreaks are raising alarm because monkeypox, which spreads through close...

The rise in COVID-19 daily new cases and daily new deaths compelled many state governments to impose local level lockdowns during April-May 2021. As of 20th April, 2021, partial lockdowns were noticed in 10 states across the country and complete lockdown was imposed in Delhi. As of 8th May, 2021, nearly the entire country was under complete lockdown as a result of either partial lockdowns and night curfews or complete...

-The Hindu The policy has absolutely no consideration for Group 3 patients who require lifelong treatment support, say organisations Caregivers to patients with ‘Rare diseases’ and affiliated organisations are dissatisfied with the National Policy for Rare diseases, 2021 announced on Wednesday. Though the document specifies increasing the government support for treating patients with a ‘rare disease’— from ₹15 lakh to ₹20 lakh — caregivers say this doesn’t reflect actual costs of treatment. There...

Often exports made by a country to the rest of the world are seen in a positive light by us. It is because exports not only earn precious foreign currencies (that can be used for importing goods and services or simply be used for building forex reserves), it also helps in generating effective demand for goods and services produced in that country and hence, contributes to economic or GDP growth....

-The Times of India NEW DELHI: Around 40% of the essential medicines in India with lowest MRP are priced significantly higher than estimated production costs, an assessment by the World Health Organisation (WHO) shows highlighting the “exorbitant” profiteering by pharmaceutical companies and the scope for lowering prices of drugs. While innovative and newer drugs for cancer, hepatitis C and Rare diseases are out of reach of many due to their unaffordable prices,...